Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

LH · Q4 2025 Earnings

Labcorp

Reported February 17, 2026

30-second summary

Q4 revenue grew 5.6% YoY to $3.52B and non-GAAP EPS came in at $4.07, with FY2025 finishing at $13.95B (+7.2%) and $16.44 — landing inside the EPS guide but missing the enterprise revenue guide low end by ~20bps. Both segments landed inside their FY revenue guide ranges (Diagnostics +7.2% at the low end, Biopharma +6.0% lower-mid), but Q4 segment growth decelerated sharply — Diagnostics to +5.5% and Biopharma to +3.4% — and that's the real story under the FY met-in-range result. Initial FY2026 guidance of $14.61B–$14.79B revenue (+4.7-6.0%) and $17.55–$18.25 EPS (~+9% at midpoint) sits above the watch-list's $17.00 floor but bakes in revenue deceleration, and management chose to reinvest the PAMA delay savings rather than flow them to EPS. The early development restructuring pivot and elevated 4%-of-revenue capex signal management is rebuilding, not harvesting.

Headline numbers

EPS

Q4 FY2025

$4.07

Revenue

Q4 FY2025

$3.52B

+5.6% YoY

Gross margin

Q4 FY2025

28.2%

Free cash flow

Q4 FY2025

$0.49B

Operating margin

Q4 FY2025

7.6%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$3.52B	+5.6%	$3.56B	-1.1%
EPS	$4.07	—	$4.18	-2.6%
Gross margin	28.2%	—	28.8%	-60bps
Operating margin	7.6%	—	11.1%	-350bps
Free cash flow	$0.49B	—	$0.28B	+75.1%

Guidance

Company significantly raised FY

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	FY2025	7.4% to 8.0% YoY growth	7.2%	-0.2 to -0.8 pts below guide range	Missed
Free Cash Flow	FY2025	$1.17 billion to $1.29 billion	$1.206 billion	-0.036 to +0.036 billion (within range at low-to-mid point)	Missed
Diagnostics Revenue Growth	FY2025	7.2% to 7.8%	5.5%	-1.7 to -2.3 pts below guide range	Missed
Biopharma Laboratory Services Revenue Growth	FY2025	5.7% to 7.1%	3.4%	-2.3 to -3.7 pts below guide range	Missed

New guidance

Metric	Period	Guide	YoY
Adjusted EPS	FY2026	$17.55 to $18.25	6.8% to 11.1% implied YoY growth vs FY2025 actual $16.44
Revenue	FY2026	$14.61 billion to $14.79 billion	4.7% to 6.0% YoY growth (as stated by company)
Diagnostics Revenue Growth	FY2026	5.0% to 6.0%	—
Biopharma Laboratory Services Revenue Growth	FY2026	3.0% to 5.0%	—
Free Cash Flow	FY2026	$1.24 billion to $1.36 billion	2.8% to 12.8% implied YoY growth vs FY2025 actual $1.206B

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted EPS	FY2025	$16.15 to $16.50	$16.44 actual	Actual $16.44 fell within prior range; prior guide $16.15–$16.50 vs FY2025 actual $16.44	Raised

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Diagnostics Laboratories	$2.73B	+5.5%
Biopharma Laboratory Services	$0.793B	+3.4%
Diagnostics Organic Revenue Growth	4.1%	—

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Diagnostics Adjusted Operating Margin	15.4%
Biopharma Adjusted Operating Margin	17.2%
Biopharma TTM Net Orders	$3.37B
Biopharma Book-to-Bill	1.09
Biopharma Backlog	$8.72B
Biopharma Next Twelve Months Backlog Conversion	$2.66B
Consolidated Adjusted Operating Margin	13.9%

Management tone

Organic volume re-acceleration → navigating FX and PAMA headwinds → operational candor and strategic rebuild.

Three quarters ago management was selling specialty volume acceleration as a structural step-change running 2-3x historical pace. Last quarter the tone shifted to "navigating headwinds." This quarter the framing turned operationally candid: management explicitly admitted miscalibration on the early development capacity bet, with Adam Schechter saying "Historically, I said that we were going to keep the excess capacity for the growth to come back, but it's been too long. Frankly, the growth has not come back to the level that we would have anticipated. So we've moved down the path to appropriately consolidate." That's a sunk-cost acknowledgment that was absent in Q2 and only hinted at via the $50M divestiture in Q3 — and it signals management is now willing to take revenue out to defend margin.

The PAMA narrative pivoted in a way that matters for the EPS bridge. In Q3 management told investors to plan for a $100M top-and-bottom-line hit with $25M of identified mitigation, framing the Results Act as bipartisan but uncertain. This quarter the legislative delay materialized through December 31, 2026, and management framed the $25M of incremental Launchpad-style savings as a contingency held in reserve should PAMA be implemented — i.e., the PAMA reprieve is funding continued reinvestment in the business rather than flowing to EPS. Investors who modeled the delay as an upside catalyst should mark that to market.

Two quarters ago Invitae was being touted as a margin tailwind that was "annualizing" through August. This quarter Schechter stated the integration is "so integrated, it's almost impossible to pull out any longer" and that the company "won't be breaking out in Vitae any longer specifically." That's not new acquisition synergy — that's reporting consolidation that removes the investor-facing benchmark. Combined with management's continued refusal to size the consumer business, the disclosure trajectory is moving away from segment transparency, not toward it.

Capex is being elevated to roughly 4% of revenue (versus historical lower levels) to fund a new 500K+ sq ft central lab facility, which Wang flagged as higher than prior years. Coupled with PAMA-savings reinvestment and ED restructuring, the FY2026 setup is a deliberate rebuild year, not a harvest year. The FY2026 FCF guide of $1.24-1.36B (+2.8-12.8%) versus EPS growth of ~9% at midpoint suggests cash conversion is being held flat-ish as capex absorbs the upside.

Management is explicitly betting that AI deployment across pathology, microbiology, psychology, and customer experience contributes to the ~9% EPS growth despite slower revenue. That's a credibility-of-execution claim that won't be testable until mid-2026 prints.

Recurring themes management leaned on this quarter:

Specialty/esoteric testing growth (now 41.5% of revenue, up from 37.5% in Q1 2023)Hospital and health system partnership expansion (13 deals signed/closed; $1B+ contributed over 3 years)Central laboratory strength with elevated book-to-bill (1.16 current, 1.09 trailing 12-month)Margin expansion through organic growth and Launchpad efficiency initiativesAI and automation deployment across pathology, microbiology, psychology, and customer experienceOncology precision testing portfolio expansion (450+ tests across stages/types of cancer)

Risks management surfaced:

ACA tax credit expiration estimated at 30 basis points of diagnostic volume reduction in 2026Early development business remaining under pressure; timing of $50M divestiture completion could impact quarterly resultsWeather volatility (January 2026 weather worse than prior year; already reflected in guidance)Large consumer genetic client financial challenges and lower referrals in Q4 (characterized as one-time)Timing of hospital/regional lab partnership approvals (slower due to state-level regulatory requirements in addition to federal approvals)

Answers to last quarter's watch list

February 2026 guidance — whether the EPS bridge absorbs PAMA cleanly — The FY2026 EPS guide of $17.55–$18.25 (midpoint $17.90) clears the $17.00 floor that would have signaled an LRP reset. PAMA was delayed through December 31, 2026, removing the $100M-gross/$75M-net headwind from the year — and the $25M of contingent mitigation savings is being held in reserve rather than flowed to EPS. The ~9% midpoint EPS growth therefore comes from Launchpad savings, AI initiatives, and underlying operations, not from a PAMA tailwind dropped to the bottom line. The bridge is intact but more fragile than it looks.

Resolved positively

Diagnostics adjusted operating margin durability — Q4 Diagnostics adj. operating margin came in at 15.4%, +150bps YoY (organic growth including Invitae), though down 90bps sequentially from Q3's 16.3%. The FY2026 Diagnostics revenue guide of +5.0-6.0% with modest margin expansion suggests management isn't projecting strong volume-leverage acceleration but is defending the YoY expansion trajectory. Status: Resolved neutrally

Biopharma TTM book-to-bill above 1.10 — TTM book-to-bill stayed at 1.09 — a second consecutive quarter below the 1.10 threshold, confirming the Q3 watch flag was a real signal rather than timing noise. Quarterly book-to-bill of 1.16 and backlog growth of +9.2% YoY provide some offset, but Q4 segment revenue grew only 3.4% (organic +0.6%).

Resolved negatively

Q4 implied segment growth deceleration — Both segments came in materially decelerated in Q4 even though FY segment guides were met: Diagnostics Q4 +5.5% (vs FY +7.2%) and Biopharma Q4 +3.4% (vs FY +6.0%). The Q4 deceleration was real and sharper than the FY met-in-range result suggests.

Resolved negatively

Consumer business quantification — Management again declined to size the consumer business, with Schechter saying the company doesn't break out the dollar amount yet because it's not at a level he believes is critical, though he expects to break it out at some point given the growth rates. The Invitae deconsolidation move runs in the same direction — less segment transparency, not more.

Not resolved

What to watch into next quarter

Q1 FY2026 Diagnostics organic growth — needs to rebound above 4.5%. Q4 organic growth of 4.1% was the weakest print since the bull thesis began. Management blamed a one-time consumer genetic client issue plus weather; either Q1 confirms that framing by snapping back above 4.5%, or the volume acceleration thesis is structurally broken.

Biopharma TTM book-to-bill — third consecutive print below 1.10 would be confirmation. Two quarters at 1.09 is a pattern in formation. A third would invalidate the BLS recovery narrative entirely and force a model of structural mid-single-digit BLS growth at best, after early development restructuring.

Early development $50M divestiture/consolidation completion and margin impact. Management quantified a ~$50M revenue reduction with margin improvement, largely completed by the end of Q2 2026. Watch Q1 and Q2 BLS adjusted operating margin against Q4's 17.2% — if it expands meaningfully, the restructuring math works; if it doesn't, the consolidation was lower-quality than advertised.

FY2026 capex run-rate vs the 4%-of-revenue framing. That implies roughly $585M of capex on the FY2026 revenue midpoint, a step up from historical levels. Watch whether Q1 cash flow reflects the elevated capex and whether management telegraphs additional facility investment beyond the disclosed central lab build.

Consumer business or Invitae/specialty breakout. With Invitae now folded into Diagnostics and consumer still unsized, the investor-facing disclosure surface has narrowed. Either management starts disclosing one of these growth lines as a separate metric by mid-2026, or the "platform pull-through" framing remains uninspectable for another year.

Sources

Labcorp Q4 2025 Form 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/920148/000092014826000098/form8-kerex991for4q25.htm
Labcorp Q4 2025 earnings call transcript (prepared remarks and Q&A)
Labcorp Q3 2025 brief (Tapebrief internal — prior coverage)
Labcorp Q2 2025 brief (Tapebrief internal — prior coverage)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.